Search PubMed⌕ Search

Biomedical subjects

J L Haybittle

Publications and source records attributed to J L Haybittle.

At least 37 records · Page 2Linked to original sources
PubMed1989

First interim progress report on the second British Institute of Radiology Fractionation Study: short versus long overall treatment times for radiotherapy of carcinoma of the laryngopharynx.

Preliminary data from a second British Institute of Radiology Fractionation Trial comparing short (less than or equal to 4 weeks) and long (greater than 4 weeks) overall treatment times are reported. The intake of patients ran from January, 1975 to December, 1985 when 611 patients with carcinoma of the laryngo-pharynx were registered in this prospective, randomized, multicentre clinical trial. No significant differences have, so far, been demonstrated between the two arms of the trial with respect to observed survival rates, tumour-free or laryngectomy-free rates. Further long-term follow-up is continuing.

Clinical Trials as Topic↗
PubMed1988

Long-term survival experience of female patients with genital cancer.

Survival analyses of patients with cancer of the cervix uteri, corpus uteri or ovary registered at Cambridge in 1960-1979 show that, although the long-term survivors had mortality rates similar to those of a normal age-matched population and might therefore be considered 'statistically cured', their risk of dying from their original cancer was still much higher than normal. Death rates from other cancers were slightly increased in cervix patients but not in corpus and ovary. At all three sites there was no evidence that deaths from non-malignant causes were increased. Only in cancer of the ovary was survival significantly better for patients registered in 1970-1979 than for patients registered in 1960-1969.

Adult↗
PubMed1987

Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.

ER content of primary tumour tissue has been examined in 704 patients presenting with operable breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any kind. ER status is related to histological grade, menopausal status, initial site of metastases and subsequent response to endocrine therapy. A significant advantage in terms of survival is found in ER positive patients which is confined to those lymph node positive at mastectomy. DFI is also significantly related to ER status in lymph node positive patients. Survival after the symptomatic presentation of metastases and the institution of endocrine therapy is prolonged in patients with ER positive tumours. The overall response rate to endocrine therapy in assessable patients with ER positive tumours is 32%. By combining the ER status and histological grade of tumour tissue, a group of patients comprising 28% of those assessable to endocrine therapy can be identified (ER positive, grade I and II) with a response rate of 46%.

Aged↗
PubMed1987

Confirmation of a prognostic index in primary breast cancer.

A prognostic index, previously derived in a group of 387 patients with primary breast cancer, has been recalculated for the same patients with over 5 years further follow-up and shown to be unchanged. The prognostic index has also been applied prospectively to a further group of 320 patients and shown to be similarly effective in identifying patients with either a very good or a very poor prognosis. It has been verified that the index applies to patients with primary breast cancer. Patients have now been divided into 5 prognostic groups, predicting 11% of patients with an almost normal survival and a further 10% with a very poor prognosis. The index is used to stratify patients to study the effects of treatment regimes within groups of similar patients.

Breast Neoplasms↗
PubMed1985

Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index.

A review of data from the British National Lymphoma Investigation (BNLI) studies of Hodgkin's disease (HD) done over the past 14 years shows (i) that systemic chemotherapy is appropriate for all clinical stages except I and IIA, and that MOPP (mustine, vincristine, procarbazine, and prednisone) courses are substantially more effective than MOP (the same without prednisone) but no better than the less toxic LOPP combinations (where chlorambucil replaces mustine); (ii) that local involved-field irradiation in stages I and IIA HD is as effective as wide-field in terms of both overall and recurrence-free survival; and (iii) that, histologically, nodular sclerosing HD can be divided into grades 1 and 2, the latter containing areas of lymphocyte depletion or numerous pleomorphic Hodgkin's cells. A multivariate analysis of factors influencing prognosis in clinical stages I and IIA disease shows that laparotomy has no significant effect but that age, sex, erythrocyte sedimentation (ESR), the presence or absence of mediastinal involvement and, especially, pathological grade are the most important factors influencing overall survival, while ESR, pathological grade, and stage of disease (I or II) correlate with recurrence-free time. A prognostic "survival" index was developed; an index of greater than 7.5 indicated a poor prognosis and that chemotherapy was perhaps more appropriate than local radiation. Laparotomy is no longer justified as a routine procedure in staging HD, although it may still be useful in special circumstances and in some research investigations.

Adult↗
PubMed1985

Patterns of flap recurrence following mastectomy.

Flap recurrence after mastectomy is divisible into three distinct entities: spot recurrence, multiple spot recurrence and field change. Spot recurrence and multiple spot recurrence are usually controlled by local measures and are not associated with any particular characteristics of the primary tumour. The field change type of flap recurrence is difficult to control and is associated with aggressive primary tumours (grade III, node positive, oestrogen receptor negative) and a very poor prognosis. The appearance of field change type of flap recurrence is an indication for systemic therapy.

Breast Neoplasms↗
PubMed1984

Death certification in cancer of the breast.

The cause of death entered on the death certificates of 193 patients originally diagnosed as having cancer of the breast was compared with information obtained from clinical records, cancer registry records, and necropsy findings to determine the accuracy of death certification and the proportion of patients who, though dying from another cause, still had overt signs of cancer of the breast. It was found that the overall error in certifying cause of death as breast cancer was small, being an underestimate of about 4%. About a third of patients with breast cancer dying from other causes had overt signs of breast cancer at the time of death.

Aged↗
PubMed1984

The Cancer Research Campaign (King's/Cambridge) trial for early breast cancer: an analysis of the radiotherapy data.

A detailed study has been made of the patients receiving routine post-operative radiotherapy in the Cancer Research Campaign trial for early breast cancer. Particular attention has been paid to the routine dose delivered and the incidence of recurrence in different areas. Little difference was apparent in the incidence of local recurrence in groups of patients receiving different levels of dosage, although there was a threefold reduction in five-year local recurrence-free rates compared with that for patients who received no irradiation. Moderate or severe telangiectasis occurred more frequently as the dose increased. When analysed in terms of survival, there was a tendency for the patients receiving more than 1510 ret to do a little better, but this was not statistically significant and could be due to some unexplained patient selection or higher dosage. There was no suggestion that irradiation might cause reduced survival.

Breast Neoplasms↗
PubMed1983

The prognostic significance of age in Hodgkin's disease: examination of 1500 patients (BNLI report no. 23).

Patients who were 50 years of age or older made up 21% of this group of 1500 patients. The survival of this age group was considerably less than that of younger patients. This difference in survival was present in both sexes, in all histological subtypes and clinical stages and in patients both with and without systemic 'B' symptoms. The overall difference in survival was only partly abolished by allowing for the reduced survival which occurs in all old people in the general population. Fewer of the older patients than the younger patients achieved complete remission. The relapse-free actuarial rate in patients who achieved complete remission appeared to be unaffected by age, being the same for the older patients as for the younger patients. However, in the event of relapse the survival of older patients was reduced.

Actuarial Analysis↗
PubMed1982

The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects.

Analysis of pathological data in the 10th year of follow-up of a multicentre trial of the management of operable breast cancer has confirmed the correlation of prognosis with tumour grade, tumour size and lymph-node status. For each factor examined there was no difference in survival between the 2 treatment groups ("watch policy" and radiotherapy) but patients in the WP group whose tumours were of Grade II or III or greater than 2 cm, or with lymph-node metastases, had a greater chance of local recurrence. Cellular reaction had no relationship with prognosis, except in patients with Grade III tumours. The clinical relevance and application of these results are discussed.

Aged↗
PubMed1982

A prognostic index in primary breast cancer.

From a multiple-regression analysis of prognostic factors and survival in a series of 387 patients with primary breast cancer, a prognostic index has been constructed, based on lymph-node stage, tumour size and pathological grade. This index is more discriminating than lymph-node stage alone, and enables a larger group of patients to be identified with a very poor prognosis.

Adult↗